CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators

SOUTH SAN FRANCISCO, Calif., June 14, 2013 /PRNewswire-iReach/ -- CoMentis, Inc. and Anvyl announced today that the companies have agreed to form Alpharmagen, a joint venture committed to discovering and developing novel modulators of the alpha7 nicotinic receptor.

"CoMentis is extremely pleased to be forming Alpharmagen in partnership with Anvyl" said Terence Kelly,Ph.D, CoMentis' President and CEO. "We believe that alpha7 modulators have the potential to become significant therapeutic agents, and we believe that the portfolio of allosteric modulators and the expertise that Anvyl brings provides a unique 2nd generation approach to the established alpha 7 agonist program that CoMentis has advanced."

"We are pleased to be joining forces with CoMentis in creating Alpharmagen" stated David Putman, Anvyl's Chief Operating Officer. The scientific programs are very complimentary and the teams are well matched in terms of their experience. We believe that we can advance compounds quickly into clinical trials."

About Alpha7 Modulators.

The alpha 7 nicotinic acetylcholine receptor is believed to play a role in cognition and modulators of this receptor in the human brain are reported to have shown promise in Phase 2 clinical trials exploring cognitive disorders associated with schizophrenia and Alzheimer's disease.

About CoMentis:


CoMentis, Inc. has its headquarters in South San Francisco. The company is engaged in the discovery and development of small- molecule drugs to treat Alzheimer's disease.

For more information about CoMentis, please visit the Company's website at www.comentis.com


Contacts:
CoMentis: Terence Kelly, President and Chief Executive Officer (650) 869-7600

About Anvyl

Anvyl LLC is based in Irvine, CA and specializes in the development of drugs for serious neurologic and psychiatric disorders. Anvyl's drug discovery approach uses targeted allosteric modulation of ion channels to correct disease.

For more information about Anvyl, please visit the Company's website at: www.anvylllc.com


Anvyl Contact: David Putman, Chief Operating Officer   
(949) 252-9211

Media Contact: daniel hunt CoMentis, 6502106160, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE CoMentis, Inc.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.